Among the available methods, our preferred approach is one that simultaneously targets both the SMN1 and SMN2 genes, because in the absence of the SMN2 signal this approach ensures exclusion of SMA diagnosis with 100% certainty. Here, SMN2 is linked to proximal spinal muscular atrophy.